Skip to main content
BrainCited
Figure 3

More Figures from This Paper

Figure 1

Figure 1
Figure 4

Figure 4
Figure 5

Figure 5

Figure 3

557 × 1122px · 582,7 Kio

Source Paper

Immunotherapy of Mild Cognitive Impairment by ω-3 Supplementation: Why Are Amyloid-β Antibodies and ω-3 Not Working in Clinical Trials?

Journal of Alzheimer's disease : JAD (2018)

PMID: 29103035

DOI: 10.3233/JAD-170579

Cite This Figure

![Figure 3: Figure 3](https://pdfs.citedhealth.com/figures/29103035/62.png)

> Source: Milan Fiala et al. "Immunotherapy of Mild Cognitive Impairment by ω-3 Supplementation: Why Are Amylo." *Journal of Alzheimer's disease : JAD*, 2018. PMID: [29103035](https://pubmed.ncbi.nlm.nih.gov/29103035/)
<figure>
  <img src="https://pdfs.citedhealth.com/figures/29103035/62.png" alt="Figure 3" />
  <figcaption>Figure 3. Figure 3<br>  Source: Milan Fiala et al. "Immunotherapy of Mild Cognitive Impairment by ω-3 Supplementation: Why Are Amylo." <em>Journal of Alzheimer's disease : JAD</em>, 2018. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/29103035/">29103035</a></figcaption>
</figure>

Preuves associées

B
Omega-3 Fatty Acids (DHA/EPA) pour Mild Cognitive Impairment (MCI)

Note B · 18 études